View by Specialty

Trending

AdobeStock_Carrots_1200x630
November 18, 2024
1 min read
Save

CDC: 1 dead in multistate outbreak of E. coli linked to organic carrots

Lupus News

SPONSORED CONTENT
Save
SPONSORED CONTENT
November 21, 2023
2 min read
Save

Stay within hydroxychloroquine ‘therapeutic threshold’ to reduce active lupus, flare risk

Stay within hydroxychloroquine ‘therapeutic threshold’ to reduce active lupus, flare risk

SAN DIEGO — Patients with lupus who maintained hydroxychloroquine blood levels of 750 ng/ml to 1,200 ng/ml exhibited 71% to 90% lower risk for high lupus disease activity, according to data presented at ACR Convergence 2023.

SPONSORED CONTENT
November 16, 2023
2 min read
Save

‘Now is the time for action’: ACR program seeks to overcome disparities in lupus care

‘Now is the time for action’: ACR program seeks to overcome disparities in lupus care

SAN DIEGO — Improving hydroxychloroquine use and reducing glucocorticoid exposure are among the top priorities of the Healthy People with Lupus 2030 initiative, which aims to address care disparities, said a speaker at ACR Convergence 2023.

Trending

AdobeStock_Carrots_1200x630
November 18, 2024
1 min read
Save

CDC: 1 dead in multistate outbreak of E. coli linked to organic carrots

SPONSORED CONTENT
November 16, 2023
2 min read
Save

Novel combination ABBV-599 improves lupus, offers ‘expanded coverage’ of pathology

Novel combination ABBV-599 improves lupus, offers ‘expanded coverage’ of pathology

SAN DIEGO — A novel combination of elsubrutinib and upadacitinib, called ABBV-599, significantly improves systemic lupus erythematosus disease activity and flares through 48 weeks, according to data presented at ACR Convergence 2023.

SPONSORED CONTENT
November 15, 2023
24 min listen
Save

It's in the Air: Silica exposure and the risk of autoimmunity, Part 4

It's in the Air: Silica exposure and the risk of autoimmunity, Part 4

What is silica? How does it impact your risk of developing autoimmunity if you inhale it, inject it or even snort it up your nose? Listen and find out!

SPONSORED CONTENT
November 15, 2023
2 min read
Save

SGLT2 inhibitors have ‘potential role’ in reducing cardiac, renal risks in lupus

SGLT2 inhibitors have ‘potential role’ in reducing cardiac, renal risks in lupus

SAN DIEGO — Patients with lupus who received sodium-glucose cotransporter-2 inhibitors demonstrated reduced risks for major adverse cardiovascular events and kidney disease, a speaker said at ACR Convergence 2023.

SPONSORED CONTENT
November 13, 2023
3 min read
Save

Pregnant patients with low anti-Ro titers have ‘little to no’ risk for fetal heart block

Pregnant patients with low anti-Ro titers have ‘little to no’ risk for fetal heart block

SAN DIEGO — Pregnant patients with very low anti-Ro antibody titers of less than 1,000 units per mL have minimal-to-no risk for fetal atrioventricular block, according to data presented at ACR Convergence 2023.

SPONSORED CONTENT
November 13, 2023
3 min read
Save

Obinutuzumab improves odds of complete renal response, cuts flare risk in lupus nephritis

Obinutuzumab improves odds of complete renal response, cuts flare risk in lupus nephritis

SAN DIEGO — Obinutuzumab use increases the chances of achieving complete renal response and lowers the risk for kidney-related events and time to flare in lupus nephritis, according to data presented at ACR Convergence 2023.

SPONSORED CONTENT
November 12, 2023
3 min read
Save

Cardiovascular events 18 times more common in pregnant patients with lupus, APS

Cardiovascular events 18 times more common in pregnant patients with lupus, APS

SAN DIEGO — Pregnant patients with concomitant systemic lupus erythematosus and antiphospholipid syndrome have an 18-fold increased risk for cardiovascular events vs. healthy pregnant controls, said a speaker at ACR Convergence 2023.

SPONSORED CONTENT
November 09, 2023
1 min read
Save

First patients dosed in clinical trial of small molecule for MS, autoimmune conditions

First patients dosed in clinical trial of small molecule for MS, autoimmune conditions

A Boston-based biopharma company announced the first participants have been dosed in its phase 1 study to assess safety, tolerability and pharmacokinetics of a novel oral, small molecule therapeutic in healthy adults.

SPONSORED CONTENT
October 30, 2023
45 min listen
Save

Autoimmunity, Part 3: The Lupus Gradient

Autoimmunity, Part 3: The Lupus Gradient

In this episode, we dig through the data of lupus in Africa and speak with experts on the Lupus Gradient, the impact of malaria and what we can learn from it all.

View more
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails